Journal article
Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease
Abstract
IntroductionPeople with chronic kidney disease (CKD) and type 2 diabetes (T2D) have an increased risk of kidney failure and cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) have shown cardiorenal protective effects. The objective of this multinational, multidatabase study was to describe the incidence of kidney and cardiovascular outcomes in separate, …
Authors
Layton JB; Ziemiecki R; Johannes CB; Pladevall-Vila M; Khan AM; Ebert N; Kovesdy CP; Christiansen CF; García-Sempere A; Kanegae H
Journal
Diabetes Therapy, Vol. 16, No. 8, pp. 1597–1614
Publisher
Springer Nature
Publication Date
8 2025
DOI
10.1007/s13300-025-01750-7
ISSN
1869-6953